⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of GRAIL, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
GRAIL, Inc.
↗Menlo Park, USA
GRAIL is a healthcare company focused on early cancer detection through its multi-cancer early detection (MCED) blood test, Galleri. The company utilizes next-generation sequencing, population-scale clinical studies, and advanced data science to identify cancer signals across more than 50 cancer types from a single blood draw.
Originally founded in 2015 as a venture backed by Illumina, GRAIL operated as a subsidiary before being spun out as an independent public company in June 2024. The company is currently in a commercial-stage phase, marketing Galleri as a laboratory-developed test while actively pursuing formal FDA premarket approval to expand clinical adoption and reimbursement.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$156M
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Illumina
STOCK
Exchange:NASDAQ
Ticker:GRAL
Market Cap:$2.96B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Galleri test)
Modalities:Diagnostics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:NHS England (NHS-Galleri Trial)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Bob Ragusa - CEO
Scientific Founders:Richard Klausner
LINKS
Website:grailbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with GRAIL, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.